EcoDrugPlus

Atpase Na+/k+ Transporting Subunit Beta 3

Ensembl ID : ENSBBBG00000016573
Gene Symbol: ATP1B3
1 Cross references
291 Possible Orthologues:

Atr Serine/threonine Kinase

Ensembl ID : ENSBBBG00000008122
Gene Symbol: ATR
3 Cross references
207 Possible Orthologues:

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSBBBG00000016725
Gene Symbol: AXL
3 Cross references
198 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSBBBG00000015611
Gene Symbol: BRAF
3 Cross references
220 Possible Orthologues:

Bcl2 Apoptosis Regulator

Ensembl ID : ENSBBBG00000005779
Gene Symbol: BCL2
3 Cross references
228 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSBBBG00000009958
Gene Symbol: BCL2L1
2 Cross references
272 Possible Orthologues:

Bcl2 Like 10

Ensembl ID : ENSBBBG00000015555
Gene Symbol: BCL2L10
2 Cross references
129 Possible Orthologues:

Bcl2 Like 2

Ensembl ID : ENSBBBG00000022924
Gene Symbol: BCL2L2
3 Cross references
64 Possible Orthologues:

Bcl2 Related Protein A1

Ensembl ID : ENSBBBG00000006836
Gene Symbol: BCL2A1
3 Cross references
133 Possible Orthologues:

C-C Motif Chemokine Receptor 1

Ensembl ID : ENSBBBG00000003103
Gene Symbol: CCR1
3 Cross references
151 Possible Orthologues:

C-C Motif Chemokine Receptor 2

Ensembl ID : ENSBBBG00000014033
Gene Symbol: CCR2
3 Cross references
150 Possible Orthologues:

C-C Motif Chemokine Receptor 4

Ensembl ID : ENSBBBG00000004569
Gene Symbol: CCR4
3 Cross references
113 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).